Literature DB >> 12594061

Surfactant protein A inhibits lipopolysaccharide-induced in vivo production of interleukin-10 by mononuclear phagocytes during lung inflammation.

Sophie Chabot1, Laurent Salez, Francis X McCormack, Lhousseine Touqui, Michel Chignard.   

Abstract

We previously demonstrated that resident alveolar macrophages from naive mice do not synthesize interleukin (IL)-10, whereas mononuclear phagocytes (MP) recruited during the lung inflammatory process are transiently competent for IL-10 production when exposed to lipopolysaccharide (LPS) in vitro. As surfactant protein A (SP-A), a member of the collectin family, inhibits LPS-induced in vitro IL-10 formation by bone marrow-derived macrophages, we studied its effect on MP under in vivo inflammatory conditions. When mice with LPS-induced inflamed lungs were given a second intranasal LPS administration, IL-10 concentration recovered in the bronchoalveolar lavage fluids varied as a function of the time interval between the two LPS doses. Thus, IL-10 concentration increased with the number of MP up to Day 3, and then decreased to undetectable values within 24 h, despite a continued increase in the number of MP. Analysis of IL-10 mRNA from purified MP indicated that gene expression correlated with the IL-10 level in the bronchoalveolar lavage fluid. In contrast to IL-10 production, SP-A concentrations during LPS-induced inflammation decreased with a nadir at Day 3, and then increased significantly within 24 h. Furthermore, intranasal administration of exogenous SP-A to mice with LPS-induced inflamed lungs led to a repression of the IL-10 production. In summary, this study demonstrates for the first time an in vivo inhibitory role of SP-A on the anti-inflammatory activity of MP, through inhibition of IL-10 production.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12594061     DOI: 10.1165/rcmb.4883

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  7 in total

1.  Cycloxygenase inhibition enhances the effects of surfactant therapy in endotoxin-induced rat model of ARDS.

Authors:  Neha Mittal; Sankar Nath Sanyal
Journal:  Inflammation       Date:  2011-04       Impact factor: 4.092

2.  Surfactant blocks lipopolysaccharide signaling by inhibiting both NFκB and PARP activation in experimental ARDS.

Authors:  Neha Mittal; Sankar Nath Sanyal
Journal:  Mol Cell Biochem       Date:  2011-04-02       Impact factor: 3.396

3.  Effect of nebulized bovine surfactant for experimental otitis media with effusion.

Authors:  Chul Ho Jang; Yong Bum Cho; Seung Eun Oh; Jeong Uk Choi; Haekyun Park; Cheol Hee Choi
Journal:  Clin Exp Otorhinolaryngol       Date:  2010-03-30       Impact factor: 3.372

4.  An antibody against the surfactant protein A (SP-A)-binding domain of the SP-A receptor inhibits T cell-mediated immune responses to Mycobacterium tuberculosis.

Authors:  Buka Samten; James C Townsend; Zvjezdana Sever-Chroneos; Virginia Pasquinelli; Peter F Barnes; Zissis C Chroneos
Journal:  J Leukoc Biol       Date:  2008-05-01       Impact factor: 4.962

5.  Effects of surfactant protein-A on the interaction of Pneumocystis murina with its host at different stages of the infection in mice.

Authors:  Michael J Linke; Alan A Ashbaugh; Judith V Koch; Linda Levin; Reiko Tanaka; Peter D Walzer
Journal:  J Eukaryot Microbiol       Date:  2009 Jan-Feb       Impact factor: 3.346

6.  Surfactant protein D inhibits TNF-alpha production by macrophages and dendritic cells in mice.

Authors:  László Hortobágyi; Sonja Kierstein; Kateryna Krytska; Xiaoping Zhu; Anuk M Das; Francis Poulain; Angela Haczku
Journal:  J Allergy Clin Immunol       Date:  2008-06-12       Impact factor: 10.793

7.  In vivo rescue of alveolar macrophages from SP-A knockout mice with exogenous SP-A nearly restores a wild type intracellular proteome; actin involvement.

Authors:  David S Phelps; Todd M Umstead; Omar A Quintero; Christopher M Yengo; Joanna Floros
Journal:  Proteome Sci       Date:  2011-10-28       Impact factor: 2.480

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.